Abstract
Drug-resistant mutations often have deleterious impacts on replication fitness, posing a fitness cost that can only be overcome by compensatory mutations. However, the role of fitness cost in the evolution of drug resistance has often been overlooked in clinical studies or in vitro selection experiments, as these observations only capture the outcome of drug selection. In this study, we systematically profile the fitness landscape of resistance-associated sites in HIV-1 protease using deep mutational scanning. We construct a mutant library covering combinations of mutations at 11 sites in HIV-1 protease, all of which are associated with resistance to protease inhibitors in clinic. Using deep sequencing, we quantify the fitness of thousands of HIV-1 protease mutants after multiple cycles of replication in human T cells. Although the majority of resistance-associated mutations have deleterious effects on viral replication, we find that epistasis among resistance-associated mutations is predominantly positive. Furthermore, our fitness data are consistent with genetic interactions inferred directly from HIV sequence data of patients. Fitness valleys formed by strong positive epistasis reduce the likelihood of reversal of drug resistance mutations. Overall, our results support the view that strong compensatory effects are involved in the emergence of clinically observed resistance mutations and provide insights to understanding fitness barriers in the evolution and reversion of drug resistance.
Original language | English |
---|---|
Article number | e1009009 |
Journal | PLoS Genetics |
Volume | 16 |
Issue number | 10 |
DOIs | |
State | Published - 21 Oct 2020 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:Copyright: © 2020 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding
The work is supported by National Institutes of Health grant AI131294 and AI145038. All works in UCLA virology core lab is supported by University of California, Los Angeles, Center For AIDS Research grant 5P30 AI028697. Lei Dai is supported by National Key R&D Program of China (2019YFA09006700), National Natural Science Foundation of China (31971513) and Shenzhen Institute of Synthetic Biology(DWKF20190001). James O. Lloyd-Smith is supported by National Science Foundation (DEB 1557022). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funders | Funder number |
---|---|
National Key R&D Program of China | 2019YFA09006700 |
Shenzhen Institute of Synthetic Biology | DWKF20190001 |
National Science Foundation | DEB 1557022 |
National Institutes of Health | AI131294, AI145038 |
National Institute of Allergy and Infectious Diseases | P30AI028697 |
University of California | 5P30 AI028697 |
National Natural Science Foundation of China | 31971513 |